DaltonBio HPV Test Kits
In February 2025, TruScreen announced its partnership with Hangzhou Dalton Biosciences Ltd, a China-based manufacturer of HPV DNA tests and laboratory equipment. This collaboration aims to distribute Dalton Bio’s HPV IVD products through TruScreen’s global network, providing TruScreen with a complementary extension to our product range.
About the HPV DNA DH series from Dalton Bio
Detects 14 high-risk HPV types linked to cervical cancer.
Differentiates HPV16/18 to support risk-based management.
Uses Hybrid Capture Technology with full-length probes for high reproducibility and fewer missed diagnoses, even when L1 regions are lost.
Hybrid Capture is a signal-amplification technique used to detect viral DNA, particularly HPV DNA, in clinical samples without PCR. DNA from cervical cells is combined with RNA probes that are complementary to HPV sequences; if HPV DNA is present, it forms DNA–RNA hybrids. These hybrids are captured by antibodies specific for DNA–RNA hybrids, and a chemiluminescent signal is produced, with the light intensity reflecting the amount of HPV DNA present.
Key features of Dalton HPV DNA tests
Fewer missed
infections
Employing full-length HPV probes and Hybrid Capture Technology helps minimise the risk of overlooking diagnoses.
Reliable negative results
A high negative predictive value ensures strong confidence.
Accurate detection of HPV-positive women
The system precisely identifies HPV positives, including genotyping the highest risks types (HPV16/18) to improve triage decisions.
Viral load insights
Relative viral load measurements help with more accurate risk assessment and follow-up planning
Easy laboratory setup
The process requires no nucleic acid extraction or amplification, saving time, staff effort, and resources
TruScreen + DaltonBio HPV =
a stronger cervical screening solution.
TruScreen and DaltonBio’s DH HPV tests work together to deliver more accurate, more efficient cervical cancer screening solution to markets who can afford or require a dual ‘screen and confirm’ methodology.
Proven clinical performance
In 2024, TruScreen was included in The COGA “Blue Book” - The Chinese Obstetricians and Gynaecologists Association Chinese Cervical Cancer Three Phases Standardized Prevention and Treatment Blue Book - citing that:
“The sensitivity of TruScreen + hrHPV is 98.4%, higher than hrHPV combined with LBC (95.9%). When TruScreen was used as a triage on HPV positive patients, its sensitivity and specificity were both higher than LBC... Note: in co-test, when HPV was negative, TruScreen’s ability to detect CIN3 lesions was 31% higher than that of LBC.”
“When different testing methods were combined, the sensitivity of TCT+HR-HPV, TruScreen+HR-HPV, and TruScreen+HR-HPV+TCT reached 100%, while the highest specificity was observed with TruScreen+HR-HPV (25.6%).
”
TruScreen’s most recent clinical performance validation in Beijing, China - Assessment of the Real-Time Photoelectric Detection Device (TruScreen) in Screening for Cervical Precancerous Lesions in Middle-Aged Women: An Observational Study - has also proven that sensitivity and specificity of cervical cancer screening can be improved when combining TruScreen with HR-HPV tests.
Talk to us
If you would like to discuss how TruScreen can support your market, we’d love to hear from you.
Can’t see the form? Email us at info@truscreen.com.
Sign up for regular
updates and
announcements.
Can’t see the form?
Email us at marketing@truscreen.com to subscribe.